PubMed Health⌕ Search

Biomedical subjects

J Treuner

Publications and source records attributed to J Treuner.

At least 109 records · Page 6Linked to original sources
PubMed1983

Adjuvant chemotherapy in osteosarcoma - effects of cisplatinum, BCD, and fibroblast interferon in sequential combination with HD-MTX and adriamycin. Preliminary results of the COSS 80 study.

In a cooperative adjuvant chemotherapy study of osteosarcoma (COSS-80), 192 patients were registered from December 1979 to March 1982. Forty-one patients have been excluded from study because of their nonadjuvant situation, therapy-limiting clinical conditions, or inadequate diagnosis. One hundred and fifty-one patients have been randomized to receive either the drug combination bleomycin + cyclophosphamide + dactinomycin (BCD) or cisplatinum (CPL) within a course of sequential multidrug chemotherapy including adriamycin (ADR) and high dose methotrexate (HDMTX). After exclusion of 51 patients with some deviation in history and/or management 100 selected patients were randomized once more to receive in addition or not fibroblast interferon after preoperative chemotherapy and surgical removal of the primary tumor. Patients were stratified for age and sex and for site and extension of tumor as well in both randomizations. Median follow up is now 12 (1-16) months. The expected 2-year disease free survival (DFS) rate of the total doubly randomized group is 78% and of the single randomized group 76%. No difference could be discerned between recombined groups receiving BCD vs CPL or interferon vs no interferon. The effect of preoperative chemotherapy on the tumor was evaluated clinically and by histopathologic grading; 66/85 (78%) patients were judged clinically as responders with pathohistologic verification of this finding in 71% of these cases. No adverse effect arose from delaying definite surgery for preoperative chemotherapy, but initial application of chemotherapy as well as planning, preparing, and performing of the surgical procedure have been facilitated. The majority of patients received some kind of limb-salvage treatment without local recurrences so far. A statistically insignificant but intriguing tendency for a slightly higher incidence of pulmonary metastases after resection as opposed to amputation could be detected. Similar to observations in the previous study COSS-77.

Adult↗
PubMed1983

Malignant ovarian tumours during childhood.

Malignant ovarian tumours in childhood are rare. Germinal cell tumours are the most common tumours and are extremely malignant, with the exception of dysgerminomas. The possibilities of therapy have improved considerably in the last 3 to 4 years, thanks to combined chemo- and radiotherapy following surgical resection of the tumour. Exact staging at the beginning of therapy is very important. A second operation, primary or as a second look procedure, is recommended after emergency operations. Therapy should be carried out in pediatric oncology centres. Because of the invasive measures, medical and psychological care are necessary after the conclusion of therapy. The rarity of these tumours should prevail upon us to organize national and international therapeutic studies.

Adenocarcinoma↗
PubMed1982

Effect of human fibroblast interferon on natural killer cell activity: stimulation in vitro and inhibition in vivo.

This paper describes the influence of human fibroblast interferon (IFN-beta) on the cytotoxic activity of natural killer cells (NK) in vitro and in vivo using the blood of healthy donors and myeloma patients. IFN-beta stimulates NK activity against all target cells tested in vitro in a dose-dependent way up to 250% of pretreatment values. At higher IFN concentrations, stimulation returned to baseline values. Stimulation was most pronounced in the lowest lymphocyte to target cell ratio. 1- to 2-h preincubation of effector cells with IFN was enough to achieve maximal stimulation. The effector cells of IFN-treated myeloma-patients, or patients with herpes zoster, showed a clear reduction of toxicity against all cells tested during the first infusion, as compared to the pretreatment values.

Cytotoxicity, Immunologic↗
PubMed1982

Subacute sclerosing panencephalitis in a brother and sister. Therapeutic trial of fibroblast interferon.

This paper describes the very rare occurrence of subacute sclerosing panencephalitis (SSPE) in two siblings: a Turkish boy and his younger sister. The clinical picture was characteristic, and the diagnosis was confirmed in both cases by appropriate laboratory examination. The interval between the occurrence of the first neurological symptoms in the boy, and subsequently in the girl was four years. Study of HLA- and 27 other polymorphic marker-systems did not reveal linkage to one of the systems tested. Therapeutic trials in the girl included intravenous and intraventricular application of a total of 87 X 10(6) U human fibroblast interferon (Hu INF-beta) over 21 days. However, up to 3 months after the end of interferon administration there were no significant changes in the girl's condition.

Adolescent↗
PubMed1982

Diagnosis of human childhood rhabdomyosarcoma of antibodies to desmin, the structural protein of muscle specific intermediate filaments.

Four embryonal rhabdomyosarcomas, one tumor diagnosed as an undifferentiated sarcoma, probably a rhabdomyosarcoma, and six different non-muscular sarcomas were investigated with antibodies specific for different intermediate filament types. The tumor cells in the rhabdomyosarcomas and the undifferentiated tumor were stained clearly by antibodies to desmin, the intermediate filament type characteristic of muscle. The staining of tumor cell by antibodies to vimentin, the intermediate filament type characteristic of certain cell types of mesenchymal origin including myoblasts, was different in these 5 cases. In one case of embryonal rhabdomyosarcoma nearly all tumor cells were stained, but in the remaining cases few or no tumor cells were positive with the vimentin antibody. In these rhabdomyosarcomas not only the large rhabdomyoblasts, but also the small undifferentiated cells were labeled by antibodies to desmin. In the latter cell type the desmin filaments were arranged typically in coils. In contrast, tumor cells in the non-muscular mesenchymal sarcomas were stained only by antibodies to vimentin but not by antibodies to desmin or prekeratin. The retention of the desmin marker characteristic of normal muscle in cases of rhabdomyosarcoma not only allowed the undifferentiated desmin-positive sarcoma to be classified as rhabdomyosarcoma but also suggests that the use of antibodies to desmin could be very helpful in the future for the diagnosis of undifferentiated rhabdomyosarcomas.

Adult↗
PubMed1982

Autoantibodies against human beta interferon following treatment with interferon.

Recently we reported the appearance of human beta interferon (HuIFN-beta) neutralizing antibodies in a patient with a nasopharyngeal carcinoma treated successfully with a preparation of HuIFN-beta. This was the first report presenting evidence for antigenicity of IFN in an homologous system. In the present report we asked whether the unusual appearance of antibodies was due to a genetic defect of the patient's cells to produce HuIFN-beta or whether the patient's cells produce an antigenically different variant of HuIFN-beta. We demonstrate that a fibroblast cell strain established from this patient produces HuIFN-beta which does not from a serological standpoint react differently from the HuIFN-beta preparation administered. The conclusion is drawn that the antibodies against therapeutic HuIFN-beta are reacting like autoantibodies with the patient's own HuIFN-beta.

Autoantibodies↗
PubMed1981

Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon.

During recent years clinical trials have shown that human leukocyte interferon (HuIFN-alpha) may be useful in the treatment of cancer, but very little has been done concerning the possible use of human fibroblast interferon (HuIFN-beta). Treuner et al. recently reported the successful treatment of a nasopharyngeal carcinoma with HuIFN-beta: in the course of IFN-therapy a HuIFN-beta neutralizing activity appeared in the serum of this patient. We report here that such activity is due to IgG antibodies--this study is the first to present evidence for antigenicity of IFN in a homologous system.

Antibody Formation↗
PubMed1981

[Neuroblastoma study NBL79-society of pediatric oncology -- report after 1 year (author's transl)].

Within 1 year 74 children with neuroblastoma were registered, 30 patients with stage I-III (= 41%) and 44 with stage IV-metastatic disease (= 59%). An aggressive chemotherapy regimen employing Adriamycine, Cyclophosphamide, Vincristine, and Dacarbazine yielded 10/24 partial and 9/24 complete remissions after 9 weeks. 5/24 children were treated less than 9 weeks so far. At the end of the chemotherapy protocol (week 33) 6 recurrences were observed; 3 of these children died. 5 patients remained in complete remission, 1 in partial remission. 12/24 of patients were not evaluable because of treatment less than 33 weeks so far. The one year run of the study is too short to evaluate the benefit of Interferon (randomized trial). The toxicity of the regimen is tolerable, including bone marrow depression, vomiting and hyperpyrexia. Breaking off therapy was only necessary in one patient.

Adolescent↗
PubMed1981

[Lethality in children with neuroblastoma (author's transl)].

32 cases of sympathetic nervous system tumours have been treated in a single pediatric oncologic center during 1970-79 and have been submitted to a follow-up analysis according to the known prognostic parameters. A high significance of prognostic staging is seen in correlation to age, stage, site of the primary, histologic differentiation, postoperative excretion of metabolic catecholamines and surgical radicality. The overall lethality in this material has been 38%, in contrast to a lethality rate of 72% in the same center during the preceding period (1960-69). The reason for this notable drop is thought to be early diagnosis leading to a combination of favourable prognostic parameters. Total surgical removal of the primary is considered the most important therapeutic factor, being exclusively sufficient in cases where the prognosis is favourable (first year of life, stage I and II). A long term lethality rate subsequent to cytotoxic treatment has been observed, so that the 2-years-survival time has to be discussed.

Adolescent↗
PubMed1981

[Pulmonary blastoma in a 4 year old girl (author's transl)].

A case of a pulmonary blastoma is presented. The tumor's histological demarcation is difficult and contested. The diagnosis was delivered by two independent pathologists. Because of the malignancy of the tumor we decided on a combined surgical-cytostatic-radiological therapy, which has not yet been done in this way. The patient was symptom-free for 6 months, she then died however, from a brain metastasis.

Carcinoma, Squamous Cell↗
PubMed1981

[Unusual course of morbus Hodgkin during remission of acute lymphatic leukemia].

6 years after the beginning of acute lymphatic leukemia and 3 years after the end of its therapy M. Hodgkin stage Ia was diagnosed in a then 18-years-old girl. From the same location--left neck--enlarged lymph nodes had been removed already during the maintenance therapy of leukemia. A malignant disease was neither proven nor excluded at that time, when signs of immunodepression were present. The patient is now in complete remission for both diseases.

Adolescent↗